NasdaqGS:MLAB

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Canada, Europe, and Japan. More Details


Snowflake Analysis

Mediocre balance sheet with moderate growth potential.


Similar Companies

Share Price & News

How has Mesa Laboratories's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MLAB has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-3.3%

MLAB

-1.1%

US Medical Equipment

-1.4%

US Market


1 Year Return

22.0%

MLAB

23.8%

US Medical Equipment

17.8%

US Market

Return vs Industry: MLAB underperformed the US Medical Equipment industry which returned 24.8% over the past year.

Return vs Market: MLAB exceeded the US Market which returned 18.5% over the past year.


Shareholder returns

MLABIndustryMarket
7 Day-3.3%-1.1%-1.4%
30 Day15.4%5.2%4.7%
90 Day17.2%6.7%8.2%
1 Year22.3%22.0%24.8%23.8%20.5%17.8%
3 Year76.7%75.0%73.9%69.4%42.2%32.7%
5 Year147.4%142.3%145.2%126.2%83.4%62.7%

Price Volatility Vs. Market

How volatile is Mesa Laboratories's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Mesa Laboratories undervalued compared to its fair value and its price relative to the market?

3.62x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: MLAB ($271.5) is trading above our estimate of fair value ($109.36)

Significantly Below Fair Value: MLAB is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MLAB is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: MLAB is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MLAB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MLAB is good value based on its PB Ratio (3.6x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is Mesa Laboratories forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

52.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MLAB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: MLAB is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MLAB's is expected to become profitable in the next 3 years.

Revenue vs Market: MLAB's revenue (6.3% per year) is forecast to grow slower than the US market (10.1% per year).

High Growth Revenue: MLAB's revenue (6.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MLAB's Return on Equity is forecast to be low in 3 years time (6.1%).


Next Steps

Past Performance

How has Mesa Laboratories performed over the past 5 years?

-24.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MLAB is currently unprofitable.

Growing Profit Margin: MLAB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MLAB is unprofitable, and losses have increased over the past 5 years at a rate of 24.7% per year.

Accelerating Growth: Unable to compare MLAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MLAB is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.5%).


Return on Equity

High ROE: MLAB has a negative Return on Equity (-0.58%), as it is currently unprofitable.


Next Steps

Financial Health

How is Mesa Laboratories's financial position?


Financial Position Analysis

Short Term Liabilities: MLAB's short term assets ($269.8M) exceed its short term liabilities ($20.5M).

Long Term Liabilities: MLAB's short term assets ($269.8M) exceed its long term liabilities ($174.0M).


Debt to Equity History and Analysis

Debt Level: MLAB's debt to equity ratio (37%) is considered satisfactory.

Reducing Debt: MLAB's debt to equity ratio has increased from 33.3% to 37% over the past 5 years.

Debt Coverage: MLAB's debt is not well covered by operating cash flow (19.7%).

Interest Coverage: MLAB is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Next Steps

Dividend

What is Mesa Laboratories's current dividend yield, its reliability and sustainability?

0.24%

Current Dividend Yield


Upcoming Dividend Payment


Dividend Yield vs Market

Notable Dividend: MLAB's dividend (0.24%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.64%).

High Dividend: MLAB's dividend (0.24%) is low compared to the top 25% of dividend payers in the US market (4.68%).


Stability and Growth of Payments

Stable Dividend: MLAB is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: MLAB is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: MLAB is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MLAB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

Gary Owens (52 yo)

3.08yrs

Tenure

US$3,485,969

Compensation

Mr. Gary M. Owens has been Chief Executive Officer, President and Director of Mesa Laboratories, Inc. since September 1, 2017. Mr. Owens joined as Chief Operating Officer in March 2017. Mr. Owens served as ...


CEO Compensation Analysis

Compensation vs Market: Gary's total compensation ($USD3.49M) is about average for companies of similar size in the US market ($USD4.48M).

Compensation vs Earnings: Gary's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Gary Owens
CEO, President & Director3.08yrsUS$3.49m0.19%
$ 2.7m
John Sakys
CFO, Chief Accounting Officer8yrsUS$1.13m0.066%
$ 909.5k
Gregory DiNoia
Senior Vice President of Commercial Operations2.92yrsUS$898.97k0.022%
$ 304.1k
Brian Archbold
Senior Vice President of Continuous Improvement2.75yrsUS$700.88k0.0046%
$ 63.0k
Helene Leone
General Counsel6.75yrsno datano data
Peter Jung
Vice President of Corporate Development & Strategy4.67yrsno datano data
Bryan Leo
Senior Vice President of Operationsno dataUS$281.45kno data
Garrett Krushefski
Senior Vice President of Operationsno dataUS$280.56kno data

3.9yrs

Average Tenure

53.5yo

Average Age

Experienced Management: MLAB's management team is considered experienced (3.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gary Owens
CEO, President & Director3.08yrsUS$3.49m0.19%
$ 2.7m
David Kelly
Independent Director10yrsUS$174.87k0.055%
$ 762.9k
Evan Guillemin
Independent Director11.67yrsUS$174.87k0.83%
$ 11.5m
John Sullivan
Chairman of the Board3.08yrsUS$196.87k1.94%
$ 26.9m
Shannon Hall
Independent Director0.42yrno datano data
John Schmieder
Independent Director5.5yrsUS$174.87k1.44%
$ 19.9m
Jennifer Alltoft
Independent Director1.58yrsUS$164.87k0.0041%
$ 56.8k

3.1yrs

Average Tenure

52yo

Average Age

Experienced Board: MLAB's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MLAB insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.1%.


Top Shareholders

Company Information

Mesa Laboratories, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mesa Laboratories, Inc.
  • Ticker: MLAB
  • Exchange: NasdaqGS
  • Founded: 1982
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$1.386b
  • Shares outstanding: 5.10m
  • Website: https://www.mesalabs.com

Number of Employees


Location

  • Mesa Laboratories, Inc.
  • 12100 West Sixth Avenue
  • Lakewood
  • Colorado
  • 80228
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MLABNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 1984
MLIDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 1984

Biography

Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Canada, Europe, and Japan. The company’s Sterilization and Disinfection ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/22 00:38
End of Day Share Price2020/10/21 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.